Article info
PDFA difficult case
Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases
- Correspondence to Dr Arthur Mageau, Department of Neurology, Fondation Ophtalmologique Adolphe de Rothschild, 75019 Paris, France; arthur_mageau{at}hotmail.fr
Citation
Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases
Publication history
- Accepted November 17, 2017
- First published December 5, 2017.
Online issue publication
March 27, 2018
Article Versions
- Previous version (27 March 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Advances in the diagnosis and management of IgG4 related disease
- IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension
- Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations
- IgG4-related hypertrophic pachymeningitis with chronic subdural haematoma
- Intracranial spread of IgG4-related disease via skull base foramina
- A case of multiple cranial nerve palsies
- Ocular adnexal IgG4-related disease: CT and MRI findings
- Rituximab for IgG4-related disease: a prospective, open-label trial
- Immunoglobulin G4-related intracranial inflammatory pseudotumours along both the oculomotor nerves
- The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease